7 completed, 4 recruiting, 1 active not recruiting, 1 enrolling by invitation. 9 Phase 2, 4 Phase 3, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Completed 6, Recruiting 2, Not yet recruiting 1 |
| Phase 3 | 4 | Recruiting 2, Active not recruiting 1, Enrolling by invitation 1 |
| Phase 1 | 3 | Completed 3 |
Follow felzartamab: new trials by email Literature Review of felzartamab trials Research Report on felzartamab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Learn About the Effects of Felzartamab on the Kidneys of Adults With Immunoglobulin A Nephropathy (IgAN) Felzartamab - Immunoglobulin A Nephropathy | Phase 2 | Not yet recruiting | Biogen | 25 | 2026-11-16 | 2026-10-22 |
| A Study to Learn About The Effects of Felzartamab on Thyroid Function and Its Safety in Adults With Graves' Disease Ages 18 to 75 Years Old Felzartamab, Placebo - Graves' Disease | Phase 2 | Recruiting | Biogen | 60 | 2026-07-30 | 2026-10-28 |
| A Study to Learn More About the Long-Term Safety and Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR) or Microvascular Inflammation (MVI) (TRANSCEND/TRANSPIRE LTE) Felzartamab - Antibody-mediated Rejection, Microvascular Inflammation | Phase 3 | Enrolling by invitation | Biogen | 201 | 2026-04-16 | 2026-11-02 |
| A Study to Learn About the Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Late Isolated Microvascular Inflammation Felzartamab, Placebo - Microvascular Inflammation | Phase 2 | Recruiting | Biogen | 81 | 2026-01-05 | 2026-10-30 |
| A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN) Felzartamab, Tacrolimus, Standard of Care IST - Primary Membranous Nephropathy | Phase 3 | Recruiting | Biogen | 180 | 2025-05-22 | 2026-09-29 |
| A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN) Felzartamab, Placebo - Immunoglobulin A Nephropathy (IgAN) | Phase 3 | Recruiting | Biogen | 454 | 2025-05-08 | 2026-10-14 |
| A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR) Felzartamab, Placebo - Antibody-mediated Rejection | Phase 3 | Active not recruiting | Biogen | 132 | 2024-12-03 | 2026-06-05 |
| A Study to Learn More About the Safety and Effects of Felzartamab in Adults With Lupus Nephritis Aged 18 to 75 Years Old Felzartamab - Lupus Nephritis | Phase 1 | Completed | HI-Bio, A Biogen Company | 14 | 2023-11-01 | 2026-07-17 |
| MOR202 for Refractory MN MOR202 - Membranous Nephropathy | Phase 2 | Completed | Mario Negri Institute for Pharmacological Research | 10 | 2021-10-22 | 2026-07-13 |
| Felzartamab in Late Antibody-Mediated Rejection Felzartamab, Placebo - Antibody-mediated Rejection | Phase 2 | Completed | Farsad Eskandary | 22 | 2021-10-06 | 2024-04-18 |
| Clinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Felzartamab (MOR202) in IgA Nephropathy Felzartamab, Placebo - Immunoglobulin A (IgA) Nephropathy | Phase 2 | Completed | HI-Bio, A Biogen Company | 54 | 2021-08-31 | 2026-04-28 |
| Efficacy, Safety and PK/PD of MOR202 in Anti-PLA2R+ Membranous Nephropathy (aMN) (NewPLACE) MOR202 - Glomerulonephritis, Membranous Nephropathy | Phase 2 | Completed | HI-Bio, A Biogen Company | 24 | 2021-01-20 | 2025-02-07 |
| Trial to Assess Safety and Efficacy of MOR202 in Anti-PLA2R + Membranous Nephropathy (aMN) MOR202 - Glomerulonephritis, Membranous, antiPLA2R Positive | Phase 1 / Phase 2 | Completed | HI-Bio, A Biogen Company | 31 | 2019-10-15 | 2025-02-24 |
| A Phase 1/2a Study of Human Anti-CD 38 Antibody MOR03087 (MOR202) in Relapsed/Refractory Multiple Myeloma MOR03087 phase 1 dose escalation, MOR03087, Dexamethasone - Multiple Myeloma | Phase 1 / Phase 2 | Completed | MorphoSys AG | 91 | 2011-07-01 | 2021-11-16 |
Glomerulonephritis, IGA (3) · Glomerulonephritis, Membranous (3) · Glomerulonephritis (1) · Graves Disease (1) · Hyperthyroidism (1) · Kidney Diseases (1) · Lupus Erythematosus, Systemic (1) · Lupus Nephritis (1) · Multiple Myeloma (1) · Urologic Diseases (1)
Biogen (7) · HI-Bio, A Biogen Company (4) · Farsad Eskandary (1) · Mario Negri Institute for Pharmacological Research (1) · MorphoSys AG (1)
United States (9) · Australia (7) · Germany (7) · Canada (6) · Argentina (5) · South Korea (5) · Spain (5) · Austria (4) · Brazil (4) · Czechia (4) · France (4) · Taiwan (4) · Belgium (3) · Italy (3) · Japan (3)
PMID 40444214, PMID 40465397, PMID 32171061, PMID 35395951, PMID 37772889, PMID 38299639, PMID 38804514, PMID 39780312, PMID 40581166, PMID 41430762, PMID 42027554
2025 (1)